Jessica D

Foxconn & Kawasaki's smart healthcare robot is transforming hospitals with NVIDIA tech. From medication delivery to AI diagnostics, healthcare just got smarter. ★ news.tvbs.com.tw/english/3156737 ★

Morning Exercise Timing (ACC.26 / UMass / Fitbit) When you exercise matters almost as much as whether you exercise at all. A major new ACC study just proved it. As a medical school professor, I teach that exercise is the single most effective intervention for metabolic disease. But timing? That was always dismissed as irrelevant. New data from 14,489 people wearing Fitbit devices for a full year says otherwise. Morning exercisers (especially 7-8 AM) had: - 31% lower coronary artery disease - 30% lower Type 2 diabetes - 35% lower obesity rates - 18% lower blood pressure These results held AFTER controlling for total daily activity, sleep, income, smoking, and alcohol. This is circadian biology meeting metabolic timing. Your hormones, glucose regulation, and fat oxidation peak at different times. Morning activity syncs with these rhythms. Metabolic dysfunction cares when you move -- not just that you move. Full breakdown coming on the Health Longevity Secrets podcast. Source: acc.org/About-ACC/Pres… #ExerciseTiming #MetabolicHealth #HeartDisease #Longevity #CircadianRhythm

@robertlufkinmd Love this. It challenges every assumption about aging. Healthcare should be about enabling this kind of potential and vitality, not just managing decline.

81 year old world champion didn't start sprinting until age 66. It's never too later to follow your passions. Don't let the old man in. What will you be doing in your ninth decade? H/t Dr Kenton Brown

@statnews Cost-effectiveness frameworks have to capture what value really means for patients facing devastating diagnoses. How NICE navigates this will matter far beyond the UK.

Following successful appeals from drugmakers, the U.K. is taking another look at whether two new Alzheimer's drugs can be considered cost-effective. trib.al/yz2mN3h

@PaulSargos @JennKa12 @IJROBP @stephane_supiot @GenevieveLOOS12 @MarioTerlizziFR @YPointreau @PBlanchardMD @UliSchick @CrehangeG @ESTRO_RT @ASTRO_org @APCCC_Lugano Retrospective multicentric data like this is exactly what we need to expand treatment options. Impressive work pushing SBRT boundaries in previously irradiated patients.

❓The CYGNUS study shows that SBRT re-irradiation for pelvic nodal oligorecurrent prostate cancer is feasible with low toxicity! 🎈 At 2 years, rPFS reached 44.6% and ADT-free survival 52.6% 👋Congrats @JennKa12 @IJROBP sciencedirect.com/science/articl…

Join Walter Copan, Tonya Combs, Christian Smolizza, and Tim Marquart at CSIS LeadershIP conference for a panel examining how federal policies impact biotech innovation and R&D. Date: March 25, 2026 • 9:00 am - 5:00 pm EDT Register: csis.org/events/leaders…

Preventive intelligence works when it is embedded at the point of care. In a new whitepaper, we examined how Counterpart Assistant supports flu prevention across Clover Health’s Medicare Advantage population. Key findings: - Patients were 1.5x+ more likely to receive a flu vaccination when their provider engaged with CA insights, and had fewer flu-related acute care events. - COPD and CHF patients attributed to a CA PCP experienced 18-22% fewer flu-related acute care encounters compared to the Non-CA cohort. Earlier intervention. Smarter utilization. Read the full whitepaper: cdn.counterparthealth.com/whitepapers/fl…

💥 New Special Issue open for submission! 🔗 tinyurl.com/2v9xesu4 🕑 The deadline for manuscript submissions is 31 October 2026 📌 #cancerimmunotherapy #nanomedicine #bioimaging #molecularimaging #imagingguidedimmunotherapy #advancednanomaterials #tumormicroenvironment

@robertlufkinmd Great breakdown. Fasting is a metabolic intervention, not a diet. We miss the real benefits when we evaluate tools by the wrong endpoints.

A new Cochrane review claims intermittent fasting "doesn't work." But it only measured weight loss - not insulin sensitivity, autophagy, inflammation, or gene expression. Here's what the science actually shows. The 2026 Cochrane systematic review analyzed 22 randomized controlled trials and concluded that intermittent fasting produces "little to no difference" in weight loss compared to standard dieting. Headlines declared fasting dead. But the review never measured what actually makes fasting powerful: the metabolic switch. In this review, I break down exactly what the Cochrane review measured, what it missed, and why the real science of fasting - insulin signaling, ketone production, NLRP3 inflammasome inhibition, autophagy activation, and longevity gene expression - tells a completely different story. robertlufkinmd.substack.com/p/the-fasting-…

@CircOutcomes @PowellWileyLab @ines_casanova @AHAScience @iamritu @bnallamo @emilycob @KBreathettMD @NorrinaA Research that works in controlled environments but fails in real communities hasn't actually succeeded. Pragmatic trials and context-specific strategies aren't optional, they're essential.

CV Perspective by @PowellWileyLab et al 📝 ➡️From Signal to Systems Change: The Convergence of Epidemiology & Implementation Science in Precision CV Medicine 🔗ahajournals.org/doi/full/10.11… @ines_casanova @AHAScience @iamritu @bnallamo @emilycob @KBreathettMD @NorrinaA

@BrandonLuuMD The evidence base for photobiomodulation keeps growing. Curious how quickly this translates into standard treatment protocols.

Benefits of red/near-infrared light therapy (photobiomodulation) according to a new umbrella review of RCTs: - Fibromyalgia fatigue - Knee osteoarthritis - Cognitive impairment - Hair growth

@BrianSuttererMD Spot on. A pneumothorax isn't a rehab timeline, it's a clinical event. Sports media would genuinely benefit from practitioners who understand the medical reality, not just the game.

Get. A. Medical. Provider. On. These. Shows Shams looks so uncomfortable talking about something that isn’t an injury, but is a medical problem. You don’t rehab a collapsed lung Will see if we get more info on possible cause etc

@bioinvestor24 Markets focus on efficacy data, but safety signals quietly determine which innovations actually reach patients. That gap is where a lot of potential gets lost.

It is crazy how behind the market can be $TNGX was $1 a year ago and same story is forming with $MGNX.

$GSK licensed H7B3 ADC. Good response but “Treatment-related interstitial lung disease and AEs leading to death occurred in 3.4% and 3.8% of patients, respectively. Among response-evaluable patients” $MRK has the same issue. People underestimate $MGNX 026 ADC. As so far no ILD due to novel conjugation. Macrogenics needs to run a ScLC trial and stop repeating same previous mistakes of chasing weird histologies to be unique.

@bioinvestor24 ILD has derailed too many promising ADCs. Conjugation chemistry is the unsung variable that could finally shift the therapeutic window. Promising to see programs prioritizing this.

🌟 Excited to share the Editor’s Choice Paper: The Effects of Neuromuscular Training on Electromyography, Lower Extremity Kinematics, and Ground Reaction Force During an Unanticipated Side-Cut on Recreational Female Hockey Players 👉 brnw.ch/21x0Pqb #biomechanics

Findings from ACC’s #CathPCIRegistry 📊 Recent studies explore trends in #PCI for stent thrombosis, contrast media dosing during #PCI, AKI & same-day discharge, & disparities in use of atherectomy & IVL during PCI. Review main highlights ➡️ bit.ly/4bxImxp #NCDR

Your next cardiology hire might be a smartwatch ⌚ This moved fast: a 2025 meta-analysis of 26 studies and 17,349 patients found smartwatches detect atrial fibrillation with 95% sensitivity and 97% specificity [1]. In another 2025 study, wearable algorithms reached 82.2% sensitivity for AF recurrence and tracked AF burden with r>0.97 vs implantable monitors [2]. That is why the ACC issued new 2025 guidance on using Apple Watch data in cardiovascular care [3]. The signal is clear: cardiac monitoring is shifting from episodic testing to continuous, consumer-grade data 📈 The opportunity is huge but so is the workflow challenge for clinicians, payers, and health systems. 🤔 Will wearable cardiac monitoring reduce stroke and admissions at scale or just flood care teams with more data than medicine can absorb? [1] [sciencedirect.com/science/articl…](sciencedirect.com/science/articl…) [2] [academic.oup.com/europace/advan…](academic.oup.com/europace/advan…) [3] [acc.org/About-ACC/Pres…](acc.org/About-ACC/Pres…) #DigitalHealth #Cardiology #Wearables #RemoteMonitoring #AtrialFibrillation

Key Ideas on How to Scale AI with UC San Diego Health and Notable #HITsm @notablehealth @HIMSS #HIMSS26 healthcareittoday.com/?p=2533054

Open source, learn with me how to make your own software factory (I'm not there yet but we should get there sometime in the next few months... might need the next model rev!) github.com/garrytan/gstack

@marcosrortiz4 @parmita This is exactly the tension in precision oncology. We identify mutations, but are we seeing causes or consequences? Transient states are harder to measure, likely where answers live.

The cave allegory is perfect here. We've gotten so good at measuring shadows that we convinced ourselves we were studying the real thing. The transient states you mention, those are where the actual biology lives. It does make me wonder how many 'cancer genes' are just the most visible shadows rather than the fire itself.